Ron de Jong
Impact in
- Hematology top 5%
- Chronic Myeloid Leukemia Treatments
- Immunology and Allergy top 5%
- Cell Adhesion Molecules Research
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 7
- Protein Degradation and Inhibitors 3
-
- Chronic Myeloid Leukemia Treatments 8
- Co-authors
- Nora Heisterkamp (10 shared papers)John Groffen (10 shared papers)Johanna ten Hoeve (2 shared papers)Morris J. Birnbaum (3 shared papers)Tilman Oltersdorf (3 shared papers)Diana W. Shineman (1 shared paper)Matthias Szabolcs (1 shared paper)Han Cho (1 shared paper)
- Journals
- Bioorganic & Medicinal Chemistry Letters (6 papers)Journal of Biological Chemistry (5 papers)Molecular Cancer Therapeutics (3 papers)Oncogene (3 papers)Anticancer Research (1 paper)
- Partner nations
- United StatesJapanNetherlands
In The Last Decade
Ron de Jong
32 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 98
- Hematology 223
- Immunology and Allergy 118
- Genetics 160
- Molecular Biology 1.1k
- Oncology 283
Countries citing papers authored by Ron de Jong
This map shows the geographic impact of Ron de Jong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron de Jong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron de Jong more than expected).
Fields of papers citing papers by Ron de Jong
This network shows the impact of papers produced by Ron de Jong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron de Jong. The network helps show where Ron de Jong may publish in the future.
Co-authors
The 25 scholars most cited alongside Ron de Jong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 484 | |
| 2 | 2010 | 224 | |
| 3 | 1995 | 117 | |
| 4 | 1995 | 114 | |
| 5 | 1997 | 75 | |
| 6 | 1993 | 49 | |
| 7 | 2010 | 48 | |
| 8 | 2006 | 46 | |
| 9 | 1997 | 42 | |
| 10 | Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice. | 2001 | 38 |
| 11 | 2013 | 37 | |
| 12 | 1993 | 37 | |
| 13 | 2013 | 32 | |
| 14 | 2006 | 31 | |
| 15 | 2018 | 30 | |
| 16 | 1998 | 30 | |
| 17 | 2018 | 27 | |
| 18 | Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth. | 2004 | 26 |
| 19 | 2002 | 24 | |
| 20 | 1998 | 17 |
About Ron de Jong
Ron de Jong is a scholar working on Molecular Biology, Hematology, Genetics, Organic Chemistry and Oncology, having authored 34 papers that have together received 1.6k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (8 papers), Chronic Lymphocytic Leukemia Research (7 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), Microtubule and mitosis dynamics (5 papers), Cancer Mechanisms and Therapy (4 papers), Protein Degradation and Inhibitors (3 papers), Quinazolinone synthesis and applications (3 papers) and Cell Adhesion Molecules Research (3 papers). The work is most often cited by research in Hematology (223 citations), Immunology and Allergy (118 citations), Genetics (160 citations), Molecular Biology (1.1k citations) and Oncology (283 citations). Ron de Jong has collaborated with scholars based in United States, Japan and Netherlands. Frequent co-authors include Nora Heisterkamp, John Groffen, Johanna ten Hoeve, Morris J. Birnbaum, Tilman Oltersdorf, Diana W. Shineman, Matthias Szabolcs, Han Cho, Thomas Ludwig and Rachael Easton. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Biological Chemistry, Molecular Cancer Therapeutics, Oncogene and Anticancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.